{
    "nctId": "NCT01941407",
    "briefTitle": "First Line Metastatic Breast Cancer Treatment (ESMERALDA)",
    "officialTitle": "A PHASE II TRIAL EVALUATING THE COMBINATION OF ERIBULIN (HALAVEN\u00ae) + BEVACIZUMAB (AVASTIN\u00ae) AS A FIRST LINE TREATMENT IN PATIENTS WITH METASTATIC HER2- BREAST CANCER",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 61,
    "primaryOutcomeMeasure": "Number of patient with non progressive disease",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \\> 18 ans\n* Patient with metastatic mammary adenocarcinoma\n* Hormone receptors ER and PR positive or negative for HER 2 negative\n\nExclusion Criteria:\n\n* Prior chemotherapy for metastatic disease\n* Previous treatment with eribulin or bevacizumab\n* Presence of symptomatic brain metastases or meningeal",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}